Today: 30 April 2026
Nu Holdings stock dips as Nubank cools off from a 52-week high with U.S. jobs report ahead
7 January 2026
1 min read

Nu Holdings stock dips as Nubank cools off from a 52-week high with U.S. jobs report ahead

New York, January 7, 2026, 09:50 EST — Regular session

Nu Holdings Ltd shares slipped about 2.2% to $17.46 in early New York trade on Wednesday, backing away from recent highs after a strong start to the year.

The pullback comes with the stock still near its 52-week high — the best level in the past year — after a two-session sprint that briefly took it above $18.

Macro data is driving the mood. U.S. private payrolls rose by 41,000 in December, missing forecasts for a 47,000 gain, ADP’s report showed on Wednesday, a day before traders shift attention to Friday’s government jobs data.

Nu jumped 5.4% on Monday to close at $17.94 after touching $18.14, then eased 0.5% on Tuesday even as it hit $18.37, StockAnalysis.com data showed. Turnover cooled as well, with about 59 million shares traded on Tuesday versus roughly 79 million on Monday.

Other U.S.-listed Brazil fintech names were also lower: StoneCo fell about 6% and PagSeguro slid about 1.8% in early trading. In the sector backdrop, Brazilian digital bank PicPay filed for a U.S. IPO on Monday, a reminder that investor appetite for fintech paper has not vanished.

The next U.S. catalyst is close. The Bureau of Labor Statistics is due to release the Employment Situation report for December 2025 at 8:30 a.m. ET on Friday, with the Consumer Price Index for December 2025 set for Jan. 13.

But the setup cuts both ways. A hotter jobs print could push rate expectations and bond yields higher, a mix that can weigh on high-multiple growth stocks; and for digital lenders, any shift in credit quality can move the tape quickly.

Stock Market Today

  • Merck Reports Q1 Loss Beats Revenue Estimates, Shares Rise
    April 30, 2026, 9:21 AM EDT. Merck (MRK) posted a Q1 loss of $1.28 per share, beating the Zacks estimate loss of $1.51, narrowing from $2.22 profit a year ago. Revenue rose to $16.29 billion, surpassing estimates by 2.44% and increasing from $15.53 billion last year. The results marked Merck's fourth consecutive quarter exceeding earnings per share (EPS) forecasts. Despite current mixed earnings revisions, the stock holds a Zacks Rank #3 (Hold), suggesting performance in line with the market. Merck shares have gained 5.4% year-to-date versus the S&P 500's 4.2% rise. The Large Cap Pharmaceuticals sector ranks in the bottom 32% of Zacks industries, which may influence Merck's stock outlook. Investors await further guidance from management and upcoming earnings estimate revisions to gauge future share movement.

Latest article

US Dollar Drops as GDP Miss and Core PCE Jump Cloud Fed Cut Bets

US Dollar Drops as GDP Miss and Core PCE Jump Cloud Fed Cut Bets

30 April 2026
The U.S. dollar fell Thursday after first-quarter GDP growth missed forecasts and core inflation accelerated, complicating the Federal Reserve’s rate outlook. The Dollar Index dropped 0.59% to 98.33, with the dollar hitting session lows against the yen after Japanese officials hinted at intervention. The Fed held rates steady Wednesday but showed division over future cuts. U.S. GDP grew at a 2.0% annualized rate, while core PCE inflation jumped to 4.3%.
QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

30 April 2026
Qualcomm shares rose 10.3% premarket Thursday after CEO Cristiano Amon said the smartphone market had bottomed and highlighted progress in data-center chips. Fiscal Q2 revenue fell 3% to $10.6 billion, with handset revenue down 13% but automotive up 38%. The Q3 forecast missed Wall Street estimates. Qualcomm expects chip sales to Chinese handset makers to recover after Q3.
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

30 April 2026
Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
Apple stock drops premarket as AAPL faces jobs data, App Store appeal, earnings clock
Previous Story

Apple stock drops premarket as AAPL faces jobs data, App Store appeal, earnings clock

Gold stocks slide as gold price pulls back; Newmont, GDX drop with U.S. payrolls ahead
Next Story

Gold stocks slide as gold price pulls back; Newmont, GDX drop with U.S. payrolls ahead

Go toTop